Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. Source
No articles found.
Interpace Diagnostics is focused on developing and commercializing molecular diagn...
Interpace Diagnostics is focused on developing ...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...
Eloxx Pharmaceuticals, Inc. is a clinical-stage...
We at Auris Medical are dedicated to developing novel pharmaceutical products for ...
We at Auris Medical are dedicated to developing...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused o...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a r...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Join the National Investor Network and get the latest information with your interests in mind.